261 related articles for article (PubMed ID: 33974005)
1. Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.
Tyan YS; Lee YP; Chuang HY; Wang WH; Hwang JJ
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33974005
[TBL] [Abstract][Full Text] [Related]
2. Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB Pathway.
Chuang HY; Lee YP; Lin WC; Lin YH; Hwang JJ
Sci Rep; 2019 Sep; 9(1):13284. PubMed ID: 31527721
[TBL] [Abstract][Full Text] [Related]
3. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
Leung JK; Tam T; Wang J; Sadar MD
Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
[TBL] [Abstract][Full Text] [Related]
6. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
[TBL] [Abstract][Full Text] [Related]
7. The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer.
Quan Y; Zhang X; Butler W; Du Z; Wang M; Liu Y; Ping H
Int J Biol Sci; 2021; 17(13):3288-3304. PubMed ID: 34512147
[TBL] [Abstract][Full Text] [Related]
8. Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models.
Schmidt KT; Chau CH; Strope JD; Huitema ADR; Sissung TM; Price DK; Figg WD
Mol Cancer Ther; 2021 May; 20(5):915-924. PubMed ID: 33632874
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk of NF-κB/P65 and LncRNA HOTAIR-Mediated Repression of MUC1 Expression Contribute to Synergistic Inhibition of Castration-Resistant Prostate Cancer by Polyphyllin 1-Enzalutamide Combination Treatment.
Xiang S; Zou P; Wu J; Zheng F; Tang Q; Zhou J; Hann SS
Cell Physiol Biochem; 2018; 47(2):759-773. PubMed ID: 29807357
[TBL] [Abstract][Full Text] [Related]
10. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
[TBL] [Abstract][Full Text] [Related]
12. Mifepristone Has Limited Activity to Enhance the
Yang Y; Li X; Mamouni K; Kucuk O; Wu D
Anticancer Res; 2017 Nov; 37(11):6235-6243. PubMed ID: 29061806
[TBL] [Abstract][Full Text] [Related]
13. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
14. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.
Gupta S; Pungsrinont T; Ženata O; Neubert L; Vrzal R; Baniahmad A
Horm Cancer; 2020 Aug; 11(3-4):182-190. PubMed ID: 32562083
[TBL] [Abstract][Full Text] [Related]
16. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
Swami U; Agarwal N
Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
[TBL] [Abstract][Full Text] [Related]
17. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
Basu HS; Wilganowski N; Robertson S; Reuben JM; Cohen EN; Zurita A; Ramachandran S; Xiao LC; Titus M; Wilding G
Prostate; 2021 Sep; 81(12):799-811. PubMed ID: 34170017
[TBL] [Abstract][Full Text] [Related]
19. Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death.
Xiang Z; Sun Y; You B; Zhang M; Huang C; Yu J; You X; Wu D; Chang C
Cell Death Dis; 2021 Jan; 12(1):68. PubMed ID: 33431795
[TBL] [Abstract][Full Text] [Related]
20. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer.
Sadowski MC; Pouwer RH; Gunter JH; Lubik AA; Quinn RJ; Nelson CC
Oncotarget; 2014 Oct; 5(19):9362-81. PubMed ID: 25313139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]